As a woman with Polycystic Ovarian Syndrome (PCOS), I welcome the latest research into GLP-1 medications—they changed my life beyond just weight loss. Diagnosed at 17, I struggled for years with symptoms, particularly insulin resistance. Despite repeated GP visits, I was often told to 'try harder' or given incorrect information about treatment options.
During the pandemic, my condition worsened due to stress and reduced activity, leading my weight to spike to 17 stone. When I sought medical help for insulin resistance, I was dismissed because my cortisol levels weren't high enough and my diabetes test was normal. At 22, I was told I was 'too young' for intervention. Later, I was wrongly informed that Metformin was no longer used for PCOS, which is factually incorrect.
Desperate to conceive, I finally secured a Metformin prescription in April 2025. Within months, I lost nearly 4 stone—more than I had managed in years. However, the medication triggered a persistent period lasting months, causing significant distress. Despite clear medical checks, my hormones remained imbalanced.
In January 2026, I returned to my GP, feeling desperate. He acknowledged that a GLP-1 injection could help but said I wasn't eligible on the NHS despite a BMI over 40. Fearing pancreatitis, I hesitated until I researched the benefits for PCOS, including improved ovarian function and insulin resistance when combined with Metformin.
I started GLP-1 treatment privately. The first week brought nausea, headaches, and heavy bleeding, but within a week, symptoms resolved. Four months later, I've lost nearly two stone (almost five stone total since April 2025), and the prolonged bleeding hasn't returned. I feel balanced and happier than I have in years.
This experience underscores why I welcome research into GLP-1 medications for PCOS. Researchers at Aston University and Sandwell and West Birmingham NHS Trust are reviewing existing studies and plan to use real-world data from fertility clinics, GP records, and weight-management services to assess effectiveness. While not a universal solution, this research offers hope for better, more personalized treatments beyond standard options like Metformin.
